The analysis of cancer screening trials in which the outcome is the incidence of late-stage disease
- 1 April 2026
- journal article
- editorial
- Published by Springer Nature in European Journal of Epidemiology
- Vol. 41 (4) , 393-394
Abstract
The National Health Service-Galleri randomized trial seeks to determine the extent to which a blood-based multi-cancer screening test can lead to a reduced incidence of a variety of cancers that are at a late stage as of the time of initial diagnosis. In February 2026, the investigators of this trial issued a news release indicating that after several years of follow-up, for a group of 12 pre-specified forms of cancer there was a lower incidence of stage IV cancer among patients in the intervention arm of the trial than in the control arm. The release stated that a group of participants whose stage IV cancer could not have been influenced by the screening – those with stage IV disease already present as of the initial screening exam – had been excluded from this analysis. We argue that while it is appropriate to restrict such an analysis to persons without prevalent stage IV cancer at the start of the trial, a valid result will be obtained only after accounting for the counterparts of these cases that are present in the trial’s control arm. We describe how this can be accomplished, and the assumptions needed for such a strategy to succeed.Keywords
Funding Information
- Division of Cancer Epidemiology and Genetics (R35 CA274442)
This publication has 5 references indexed in Scilit:
- Design considerations and challenges in the CHinA National CancEr Screening (CHANCES) trial and Tomosynthesis Mammographic Imaging Screening Trial (TMIST)JNCI Monographs, 2025
- Screening for Cancer Precursor Lesions: Assessing the Impact on Cancer Incidence in Randomized TrialsEpidemiology, 2023
- Cell-Free DNA–Based Multi-Cancer Early Detection Test in an Asymptomatic Screening Population (NHS-Galleri): Design of a Pragmatic, Prospective Randomised Controlled TrialCancers, 2022
- Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNAAnnals of Oncology, 2020
- Healthy screened bias in epidemiologic studies of cancer incidence.1996